5F-CUMYL-P7AICA: Difference between revisions
CSV import |
CSV import |
||
| Line 3: | Line 3: | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = 477002547 | | verifiedrevid = 477002547 | ||
| image = 5F-CUMYL-P7AICA_Structure.svg | | image = 5F-CUMYL-P7AICA_Structure.svg | ||
| image_size = 200px | |||
| image_alt = Chemical structure of 5F-CUMYL-P7AICA | |||
| IUPAC_name = 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide | |||
| CAS_number = 1400742-14-7 | |||
| ChemSpiderID = 58191434 | |||
| UNII = 7F5F9N0R6H | |||
| PubChem = 119025345 | |||
| C=23 | |||
| H=27 | |||
| F=1 | |||
| N=2 | |||
| O=1 | |||
}} | }} | ||
'''5F-CUMYL-P7AICA''' is a synthetic cannabinoid that has been used in | '''5F-CUMYL-P7AICA''' is a synthetic [[cannabinoid]] that has been used in [[designer drug]]s. It is a potent agonist of the [[cannabinoid receptor]]s, which are part of the [[endocannabinoid system]]. | ||
==Chemical | ==Chemical structure and properties== | ||
5F-CUMYL-P7AICA is | [[File:5F-CUMYL-P7AICA_Structure.svg|thumb|right|Chemical structure of 5F-CUMYL-P7AICA]] | ||
5F-CUMYL-P7AICA is chemically classified as an indole-based synthetic cannabinoid. Its IUPAC name is 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide. The compound features a fluorinated pentyl chain, which is a common modification in synthetic cannabinoids to enhance potency and metabolic stability. | |||
==Pharmacology== | ==Pharmacology== | ||
5F-CUMYL-P7AICA acts as a | 5F-CUMYL-P7AICA acts as a full agonist at the [[CB1 receptor]] and [[CB2 receptor]], which are the primary receptors of the endocannabinoid system. These receptors are involved in a variety of physiological processes including pain sensation, mood, and memory. The activation of these receptors by synthetic cannabinoids can lead to effects similar to those of [[tetrahydrocannabinol]] (THC), the active component of [[cannabis]]. | ||
== | ==Effects and toxicity== | ||
The | The effects of 5F-CUMYL-P7AICA are similar to those of other synthetic cannabinoids, which can include euphoria, altered perception, and relaxation. However, synthetic cannabinoids can also cause severe adverse effects such as [[tachycardia]], [[hypertension]], [[nausea]], [[vomiting]], [[anxiety]], and [[psychosis]]. The toxicity of 5F-CUMYL-P7AICA is not well-documented, but it is likely to be similar to other synthetic cannabinoids, which have been associated with serious health risks and fatalities. | ||
== | ==Legal status== | ||
The legal status of 5F-CUMYL-P7AICA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. It is often included in legislation targeting synthetic cannabinoids and other [[novel psychoactive substances]]. | |||
== | ==Synthesis== | ||
5F-CUMYL-P7AICA | The synthesis of 5F-CUMYL-P7AICA involves the reaction of an indole-3-carboxylic acid derivative with a fluorinated alkyl halide, followed by amide formation with an appropriate amine. The synthetic routes for these compounds are often designed to be straightforward to facilitate clandestine production. | ||
==Related pages== | ==Related pages== | ||
* [[Synthetic cannabinoids]] | * [[Synthetic cannabinoids]] | ||
* [[Cannabinoid receptor]] | * [[Cannabinoid receptor]] | ||
* [[Designer drug]] | |||
* [[Endocannabinoid system]] | * [[Endocannabinoid system]] | ||
[[Category:Synthetic cannabinoids]] | [[Category:Synthetic cannabinoids]] | ||
[[Category: | [[Category:Designer drugs]] | ||
Latest revision as of 06:12, 16 February 2025
Synthetic cannabinoid
| 5F-CUMYL-P7AICA | |
|---|---|
| File:5F-CUMYL-P7AICA Structure.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1400742-14-7 |
| PubChem | 119025345 |
| DrugBank | |
| ChemSpider | 58191434 |
| KEGG | |
5F-CUMYL-P7AICA is a synthetic cannabinoid that has been used in designer drugs. It is a potent agonist of the cannabinoid receptors, which are part of the endocannabinoid system.
Chemical structure and properties[edit]
5F-CUMYL-P7AICA is chemically classified as an indole-based synthetic cannabinoid. Its IUPAC name is 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide. The compound features a fluorinated pentyl chain, which is a common modification in synthetic cannabinoids to enhance potency and metabolic stability.
Pharmacology[edit]
5F-CUMYL-P7AICA acts as a full agonist at the CB1 receptor and CB2 receptor, which are the primary receptors of the endocannabinoid system. These receptors are involved in a variety of physiological processes including pain sensation, mood, and memory. The activation of these receptors by synthetic cannabinoids can lead to effects similar to those of tetrahydrocannabinol (THC), the active component of cannabis.
Effects and toxicity[edit]
The effects of 5F-CUMYL-P7AICA are similar to those of other synthetic cannabinoids, which can include euphoria, altered perception, and relaxation. However, synthetic cannabinoids can also cause severe adverse effects such as tachycardia, hypertension, nausea, vomiting, anxiety, and psychosis. The toxicity of 5F-CUMYL-P7AICA is not well-documented, but it is likely to be similar to other synthetic cannabinoids, which have been associated with serious health risks and fatalities.
Legal status[edit]
The legal status of 5F-CUMYL-P7AICA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. It is often included in legislation targeting synthetic cannabinoids and other novel psychoactive substances.
Synthesis[edit]
The synthesis of 5F-CUMYL-P7AICA involves the reaction of an indole-3-carboxylic acid derivative with a fluorinated alkyl halide, followed by amide formation with an appropriate amine. The synthetic routes for these compounds are often designed to be straightforward to facilitate clandestine production.
